Current guidelines from the American College of Rheumatology advocate adding a biologic, such
as etanercept, if symptoms persist.
Not exact matches
The major players in the arthritis drug market include Remicade ® (infliximab), Humira ® (adalimumab), Enbrel ® (
etanercept), Cimzia ® (certolizumab pegol) and Simponi ® (golimumab), while biosimilars of the above
as well
as new drugs with novel mechanisms of action are under development.
The first class, known
as TNF blockers (or inhibitors), targets proteins in the immune system and includes drugs such
as Enbrel (
etanercept) and Humira (adalimumab).
• NSAIDs such
as ibuprofen (Advil and Motrin) and naproxen (Aleve) • Corticosteroids • DMARDs such
as methotrexate (Trexall) and leflunomide (Arava) • Biologic therapies (TNF - alpha blockers) such
as adalimumab (Humira),
etanercept (Enbrel), and infliximab (Remicade • Immunosuppressants such
as cyclosporine (Neoral, Gengraf, Sandimmune) and azathioprine (Imuran)